What is the potential of ADSC?
Pier Ivona
|
Adipose tissue is a rich and very convenient source of cells for regenerative medicine therapeutic approaches. Due to their wide availability and ability to differentiate into other tissue types of the mesoderm, including bone, cartilage, muscle, and adipose, ADSCs may serve a wide variety of applications. Adipose stem cells have been utilised in studies addressing osteoarthritis, diabetes mellitus, heart disease and soft tissue regeneration and reconstruction after mastectomy and facial repair. Various delivery systems and scaffolds to incorporate adipose stem cells have also been established. Adipose stem cells have been studied in vitro and in vivo. Much information in vitro has been obtained on adipose stem cell potency and biology as a function of donor gender, body mass index, and anatomical location. Further in vitro studies have examined the various cell populations amongst the heterogeneous population within the SVF from which ADSCs are obtained.
Tell us about your device that isolates ADSC?
MyStem SVF system is a specially designed medical device to isolate ADSCs or SVF. The device is a completely closed and sterile system for automated adipose tissue processing, in a safe and effective way. The device uses a cell selection technology based on cell-size segregation. This technology allows a quick selection of precursor cells naturally present in lipoaspirate liquid fraction. Collecting a cocktail of regenerative cells from LAF without expensive machines and potentially harmful enzymes, opens a new range of applications for regenerative surgery, from burns, scars, wounds to orthopaedic diseases both in day-hospitals and operating rooms due to the small amount of harvested tissue needed. This device allows surgeon to get the entire SVF cells cocktail that is proved to be more effective than single lineage-expanded cells in a safe and closed system.
How is your device different from the already existing devices in the market?
All existing devices process adipose tissue using a potentially harmful enzyme and a big and expensive machine. Our system is a simpler, safer and cheaper solution for obtaining regenerative cells cocktail from a small amount of lipoaspirate. It is the only medical device approved in Europe that offers hospitals and clinics the ability to extract stem and regenerative cells from lipoaspirate liquid fraction in a sterile, cost-effective manner without time consuming manual processing.
Are there any published studies with your devices for automated adipose tissue processing?
Yes, we are submitting our validation study soon to several high-impact factor scientific journals.
What is the regulatory status of the device?
Is MyStem easy to use?
Yes, absolutely. From early prototypes to current device being user-friendly was our first objective and commitment. With the most compact size, simplicity that enables all processes to be done with one button, and a closed system that protects from air contamination this device is very user friendly.
Who uses your technology and how much does it cost ($)?
Our customers are in orthopaedics, plastic surgery, dermatology, spine surgery. Our pricing strategy is to keep our technology affordable for high-quality hospitals and clinics in countries with low budget. Our efforts to optimise the technology allow us to price our device slightly cheaper than other similar technologies. If the Indian market, will support our efforts with good sales, we are confident to lower our price in the future. According to a research, current global stem cell market size is about $4.2 billion. The MyStem SVF procedure is not very expensive compared to the existing procedures. New cost-effective technology does impact cost. The cost of any stem cell therapy is almost the same as any conventional surgical procedure. It would perhaps cost as much as Rs 50,000-75,000 for one course of stem cell therapy and the number of courses and duration would obviously depend on patient improvement. The cost of therapy will depend on procedures involved in procuring the stem cells, harvesting, culturing and characterisation including quality control of all procedures.
Is this device being used in India?
Not yet, we are in the registration phase right now, hoping to serve Indian customers as soon as possible.